top of page

ABOLOGIX obtains positive pre-clinical proof-of-concept results with its monoclonal antibody H225

  • Jul 25, 2019
  • 1 min read

Geneva, Switzerland, July 24, 2019 – Recombinant monoclonal antibody H225, a blocker of JAM-C (Junction Adhesion Molecule C) generates impressive efficacy data in a Mantle Cell Lymphoma animal model.


 
 
 

Comments


bottom of page